Observational studyInvestigational new drugs2020

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.

Kenichi Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.